Mr. Neil Solomons reports
AURINIA ANNOUNCES VOCLOSPORIN MEETS 48-WEEK REMISSION ENDPOINTS, ACHIEVING HIGHEST COMPLETE REMISSION RATE OF ANY GLOBAL LUPUS NEPHRITIS STUDY
Aurinia Pharmaceuticals Inc. has provided top-line results from its
phase IIb Aura-LV study in lupus nephritis (LN). At 48 weeks, the
trial met the complete and partial remission (CR/PR) end points,
demonstrating statistically significantly greater CR and PR in patients
in both low dose (23.7 milligrams of voclosporin twice daily (p is less than 0.001)) and high
dose (39.5 mg twice daily (p is equal to 0.026)) cohorts versus the control group.
Each arm of the study included the current standard of care of
mycophenolate mofetil (MMF) as background therapy and a forced steroid
taper to five mg/day by week eight and 2.5 mg by week 16. No unexpected safety
signals were observed and there were no additional deaths in the
voclosporin treated patients; however, there were three deaths and one
malignancy reported in the control arm after completion of the study
treatment period. Additional data analyses for the Aura study at 48
weeks will be released at future corporate, medical and scientific
meetings.
"Lupus nephritis (LN) is one of the most severe complications of
systemic lupus erythematosus. The current treatments of LN are toxic and
the complete renal response rates are unacceptably low. For the last
several years the community of lupus researchers in collaboration with
the pharmaceutical industry have been engaged in finding more effective
therapies for LN, but success has been difficult to achieve," said Brad
Rovin, MD, FASN, director of nephrology and vice-chairman of research
for the department of internal medicine at the Ohio State University
Wexner Medical Center. "The Aura trial's long-term results convincingly
demonstrate that the addition of voclosporin to standard of care
treatment is superior to standard of care alone. These data are not only
statistically significant, but clinically important. Twice as many
patients given 23.7 mg voclosporin twice daily achieved a complete renal
response compared to those treated with placebo. This is an impressive
renal response rate and these results may shift the treatment paradigm
of LN. Based on these encouraging data, I am looking forward to the
phase III trial of voclosporin in LN."
THE 24- AND 48-WEEK TOP-LINE EFFICACY RESULTS
End point Treatment 24 weeks Odds ratio P-value* 48 weeks Odds ratio P-value*
Complete remission 23.7 mg VCS BID 33% 2.03 p=.045 49% 3.21 p<.001
39.5 mg VCS BID 27% 1.59 p=.204 40% 2.10 p=.026
Control arm 19% NA NA 24% NA NA
Partial remission 23.7 mg VCS BID 70% 2.33 p=.007 68% 2.34 p=.007
39.5 mg VCS BID 66% 2.03 p=.024 72% 2.68 p=.002
Control arm 49% NA NA 48% NA NA
* All p-values are versus control.
"We are grateful to both the patients and investigators who have worked
with us on this groundbreaking program. Voclosporin is the first and
only treatment candidate that has demonstrated such a clear treatment
effect for LN patients," said Neil Solomons, MD, Aurinia's chief medical
officer. "These data provide us with tremendous confidence that we can
execute a successful phase III program and make a meaningful impact on
patients' lives."
"Lupus nephritis carries with it life-threatening complications,
including kidney failure. The treatment of the disease is challenging
and steroid side effects are often difficult for patients to endure. The
National Kidney Foundation supports the development of steroid-sparing
treatment options and we look forward to following the results of the
phase III trial," said Joseph Vassalotti, MD, chief medical officer,
National Kidney Foundation.
Conference call and webcast details
Aurinia will host a
conference call and webcast tomorrow, March 2, 2017, at 8:30 a.m. Eastern
Standard Time to provide an overview of the Aura 48-week top-line
results. In order to participate in the conference call, please dial
1-877-407-9170 (toll-free United States and Canada). An audio webcast can be
accessed under "news/events" through the "investors" section of the
Aurinia corporate website.
A replay of the webcast will be available on Aurinia's website.
About Aura-LV
The Aura-LV study (Aurinia urinary
protein reduction in active lupus with voclosporin) is a 48-week study
comparing the efficacy of two doses of voclosporin added to current
standard of care of MMF against standard of care with placebo in
achieving CR in patients with active LN. All arms also received low
doses of corticosteroids as background therapy. Two hundred sixty-five patients were
enrolled at centres in 20 countries worldwide. On entry to the study,
patients were required to have a diagnosis of LN according to
established diagnostic criteria (American College of Rheumatology) and
clinical and biopsy features indicative of highly active nephritis. The
24-week primary and secondary end points were released in third quarter 2016 where
the primary and all secondary end points were met. CR is a composite
end point that includes: confirmed UPCR of equal to 0.5 mg/mg; normal, stable
renal function (equal to 60 millilitres per min per 1.73 square metre or no confirmed decrease
from baseline in eGFR of equal to 20 per cent); presence of sustained, low dose steroids
(equal to 10 mg prednisone from week 16 to 24); and no administration of rescue
medications. PR in the trial is measured by a 50-per-cent reduction in UPCR
with no concomitant use of rescue medication.
About voclosporin
Voclosporin, an investigational
drug, is a novel and potentially best-in-class calcineurin inhibitor
(CNI) with clinical data in over 2,200 patients across indications.
Voclosporin is an immunosuppressant, with a synergistic and dual
mechanism of action that has the potential to improve near- and
long-term outcomes in LN when added to standard of care (MMF). By
inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell
mediated immune responses. It is made by a modification of a single
amino acid of the cyclosporine molecule which has shown a more
predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency, an altered metabolic profile and potential for
flat dosing. The company anticipates that upon regulatory approval,
patent protection for voclosporin will be extended in the United States
and certain other major markets, including Europe and Japan, until at
least October, 2027, under the Hatch-Waxman Act and comparable laws in
other countries.
About lupus nephritis (LN)
LN in an inflammation of
the kidney caused by systemic lupus erythematosus (SLE) and represents
a serious progression of SLE. SLE is a chronic, complex and often
disabling disorder, and affects more than 500,000 people in the United
States (mostly women). The disease is highly heterogeneous, affecting a
wide range of organs and tissue systems. It is estimated that as many as
60 per cent of all SLE patients have clinical LN requiring treatment. Unlike
SLE, LN has straightforward disease outcomes where an early response
correlates with long-term outcomes, measured by proteinuria. In patients
with LN, renal damage results in proteinuria and/or hematuria and a
decrease in renal function as evidenced by reduced estimated glomerular
filtration rate (eGFR), and increased serum creatinine levels. LN is
debilitating and costly and if poorly controlled, LN can lead to
permanent and irreversible tissue damage within the kidney, resulting in
end stage renal disease (ESRD), thus making LN a serious and potentially
life-threatening condition.
About Aurinia Pharmaceuticals Inc.
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN. The company is headquartered in Victoria, B.C., and
focuses its development efforts globally.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.